ESC 365 - Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study

ESC Professional Premium Access

Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study

Session: Novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

Topic: Hypertrophic Cardiomyopathy

Speaker: Doctor P. Garcia-Pavia (Majadahonda, ES)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Pablo Garcia-Pavia

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Spain)

81 presentations

21 followers

4 more presentations in this session

State-of-the-art lecture on novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

Speaker: Doctor C. Ho (Boston, US)

Clinical application of biomarkers in obstructive hypertrophic cardiomyopathy: insights from SEQUOIA-HCM

Speaker: Doctor C. Coats (Glasgow, GB)

Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in preclinical individuals with an HCM sarcomeric gene mutation

Speaker: Mr B. Van Driel (Amsterdam, NL)

Aficamten in patients with obstructive hypertrophic cardiomyopathy: an integrated safety analysis

Speaker: Doctor A. Masri (Portland, US)

Access the full session

Novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

Speakers: Doctor P. Garcia-Pavia, Doctor C. Ho, Doctor C. Coats, Mr B. Van Driel, Doctor A. Masri

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources